Cyclic HIV protease inhibitors: Synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas

Journal of Medicinal Chemistry

Volumn 39, Issue 18, 1996, Pages 3514-3525

  Lam, Patrick Y S ^a   Ru, Yu ^a   Jadhav, Prabhakar K ^a   Aldrich, Paul E ^a   DeLucca, George V ^a   Eyermann, Charles J ^a   Chang, Chong Hwan ^a   Emmett, George ^a   Holler, Edward R ^a   Daneker, Wayne F ^a   Li, Liangzhu ^a   Confalone, Pat N ^a   McHugh, Robert J ^a   Han, Qi ^a   Li, Renhua ^a   Markwalder, Jay A ^a   Seitz, Steven P ^a   Sharpe, Thomas R ^a,b   Bacheler, Lee T ^a   Rayner, Marlene M ^a   Klabe, Ronald M ^a   Shum, Linyee ^a,c   Winslow, Dean L ^a,d   Kornhauser, David M ^a   Jackson, David A ^a   Erickson Viitanen, Susan ^a   Hodge, C Nicholas ^a   more..

^a DUPONT COMPANY   (United States)

^b OsteoArthritis Sciences Inc   (United States)

^c Department of Pharmacokinetics and Drug Metabolism   (United States)

^d AGOURON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4,7 DIBENZYL 2,3,4,5,6,7 HEXAHYDRO 5,6 DIHYDROXY 1,3 BIS[4 (HYDROXYMETHYL)BENZYL] 2H 1,3 DIAZEPIN 2 ONE; ANTIVIRUS AGENT; PROTEINASE INHIBITOR; UREA DERIVATIVE; WATER;

ARTICLE; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME BINDING; HUMAN IMMUNODEFICIENCY VIRUS; STRUCTURE ACTIVITY RELATION;

ANIMALS; HIV PROTEASE INHIBITORS; HUMANS; MOLECULAR CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; UREA;

EID: 9544235162     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9602571     Document Type: Article

References (85)

1. For recent reviews, see: (a) Debouck, C. The HIV-1 Protease as a Therapeutic Target for AIDS. AIDS Res. Human Retroviruses 1992, 8, 153-164.
2. (b) Katz, R. A.; Skalka, A. M. Annu. Rev. Biochem. 1994, 63, 133-173.
3. (a) Kohl, N. E.; Emini, E. A.; Schleif, W. A.; Davis, L. J.; Heimbach, J. C.; Dixon, R. A. F.; Scolnick, E. M.; Sigal, I. S. Active Human Immunodeficiency Virus Protease is Required for Viral Infectivity. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 4686-4690.
4. (b) Peng, C.; Ho, B. K.; Chang, T. W.; Chang, N. T. Role of Human Immunodeficiency Virus Type 1-Specific Protease in Core Protein Maturation and Viral Infectivity. J. Virol. 1989, 63, 2550-2556.
5. (a) Vella, S. HIV Therapy Advances. Update on a Proteinase Inhibitor. AIDS 1994, 8 (Suppl. 3), S25-29.
6. (b) Pollard, R. B. Use of Proteinase Inhibitors in Clinical Practice. Pharmacotherapy 1994, 14, 21S-29S.
7. (c) Vacca, J. P.; Dorsey, B. D.; Schlief, W. A.; Levin, R. B.; McDaniel, S. L.; Darke, P. L.; Zugay, J.; Quintero, J. C.; Blahy, O. M.; Roth, E.; Sardana, V. V.; Schlabach, A. J.; Graham, P. I.; Condra, J. H.; Gotlib, L.; Holloway, M. k.; Lin, J.; Chen, I.-W.; Ostovic, D.; Anderson, P. S.; Emini, E. A.; Huff, J. R. An Orally Bioavailable Human Immunodeficiency Virus Type-1 Protease Inhibitor. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 4096-4100.
8. (d) Wei, X.; Ghosh, S. K.; Taylor, M. E.; Johnson, V. A.; Emini, E. A.; Deutsch, P.; Lifson, J. d.; Bonhoeffer, S.; Nowak, M. A.; Hahn, B. H.; Saag, M. S.; Shaw, G. M. Viral Dynamics in Human Immunodeficiency Virus Type 1 Infection. Nature 1995, 373, 117-122.
9. (e) Kempf, D.; Marsh, K. C.; Denissen, J. F.; McDonald, E.; Vasavanonda, S.; Flentge, C. A.; Green, B. G.; Fino, L.; Park, C. H.; Kong, X.-P.; Wideburg, N. E.; Saldivar, A.; Ruiz, L.; Kati, W. M.; Sham, H. L.; Robins, T.; Stewart, K. D.; Hsu, A.; Plattner, J. J.; Leonard, J. M.; Norbeck, D. W. ABT-538 is a Potent Inhibitor of Human Immunodeficiency Virus Protease with High Oral Bioavailability in Humans. Proc. Natl. Acad. Sci. U.S.A 1995, 92, 2484-2488.
10. (f) Ho, D. D.; Neumann, A. U.; Perelson, A. S.; Chen, W.; Leonard, J. M.; Markowitz, M. Rapid Turnover of Plasma Virions and CD4 Lymphocytes in HIV-1 Infection. Nature 1995, 373, 123-126.
11. (g) Kitchen, V. S.; Skinner, C.; Ariyoshi, K.; Lane, E. A.; Duncan, I. B.; Burckhardt, J.; Burger, H. U.; Bragman, K.; Pinching, A. J.; Weber, J. N. Safety and Activity of Saquinavir in HIV Infection. Lancet 1995, 345, 952-955.
12. (a) Wlodawer, A.; Erickson, J. W. Structure-based Inhibitors of HIV-1 Protease. Annu. Rev. Biochem. 1993, 62, 543-585.
13. (b) Appelt, K. Crystal Structures of HIV-1 Protease-inhibitor Complexes. Perspect. Drug Discovery Des. 1993, 1, 23-48.
14. 2 Symmetric Inhibitors of HIV Protease. J. Med. Chem. 1990, 33, 2687-2689. For reviews, see:
15. (b) Norbeck, D. W.; Kempf, D. J. HIV Protease Inhibitors. Annu. Rep. Med. Chem. 1991, 26, 141-160.
16. (c) Tomasselli, A. G.; Howe, W. J.; Sawyer, T. K.; Wlodawer, A.; Heinrikson, R. L. The Complexities of AIDS: An Assessment of the HIV Protease as a Therapeutic Target. Chim. Oggi 1991, 6-27.
17. (d) Huff, J. R. HIV Protease: A Novel Chemotherapeutic Target for AIDS. J. Med. Chem. 1991, 34, 2305-2314.
18. (e) Martin, J. A. Recent Advances in the Design of HIV Proteinase Inhibitors. Antiviral Res. 1992, 17, 265-278.
19. (f) Thaisrivaongs, S. HIV Protease Inhibitors. Annu. Rep. Med. Chem. 1994, 29, 133-144.
20. (g) Kempf, D. J. Progress in the Discovery of Orally Bioavailable Inhibitors of HIV Protease. Perspect. Drug Discovery Des. 1994, 2, 427-436.
21. (h) Gait, M. J.; Karn, J. Progress in Anti-HIV Structure-based Drug Design. TiBTECH 1995, 13, 430-437.
22. (i) West, M. L.; Fairlie, D. P. Targeting HIV-1 Protease. A Test of Drug-design Methodologies. TiPS 1995, 16, 67-74.
23. (j) De Clercq, E. Toward Improved Anti-HIV Chemotherapy: Therapeutic Strategies for Intervention with HIV Infections. J. Med. Chem. 1995, 38, 2491-2517.
24. (k) Boehme, R. E.; Borthwick, A. D.; Wyatt, P. G. Antiviral Agents. Annu. Rep. Med. Chem. 1995, 30, 139-149.
25. (a) Jacobsen, H.; Yasargil, K.; Winslow, D. L.; Craig, J. C.; Krohn, A.; Duncan, I. B.; Mous, J. Characterization of Human Immunodeficiency Virus Type 1 Mutants with Decreased Sensitivity to Proteinase Inhibitor Ro 31-8959. Virology 1995, 206, 527-534.
26. (b) Markowitz, M. M.; Mo, H.; Kempf, D. J.; Norbeck, D. W.; Bhat, T. N.; Erickson, J. W.; Ho, D. Selection and Analysis of Human Immunodeficiency Virus Type 1 Variants with Increased Resistance to ABT-538, a Novel Protease Inhibitor. J. Virol. 1995, 69, 701-706.
27. (c) Condra, J. H.; Schlelf, W. A.; Blahy, O. M.; Gabryelski, L. J.; Graham, D. J.; Quintero, J. C.; Rhodes, A.; Bobbins, H. L.; Roth, E.; Shivaprakash, M.; Titus, D.; Yang, T.; Teppler, H.; Squires, K. E.; Deutsch, P. J.; Emini, E. A. In Vivo Emergence of HIV-1 Variants Resistant to Multiple Protease Inhibitors. Nature 1995, 374, 569-571.
28. (d) Ridky, T.; Leis, J. Development of Drug Resistance to HIV-1 Protease Inhibitors. J. Biol. Chem. 1995, 270, 29621-29623.
29. (a) Swain, A. L.; Miller, M. M.; Green, J.; Rich, D. H.; Schneider, J.; Kent, S. B. H.; Wlodawer, A. X-ray Crystallographic Structure of a Complex Between a Synthetic Protease of Human Immunodeficiency Virus 1 and a Substrate-based Hydroxyethylamine Inhibitor. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 8805-8809.
30. 2 Symmetric Inhibitor Complexed to HIV-1 Protease. Science 1990, 249, 527-532.
31. (a) Rahuel, J.; Priestle, J. P.; Grutter, M. G. The Crystal Structures of Recombinant Glycosylated Human Renin Alone and in Complex with a Transition State Analog Inhibitor. J. Struct. Biol. 1991, 107, 227-236.
32. (b) Dhanaraj, V.; Dealwis, C. G.; Frazao, C.; Badasso, M.; Sibanda, B. L.; Tickle, I. J.; Cooper, J. B.; Driessen, H. P. C.; Newman, M.; Aguilar, C.; Wood, S. P.; Blundell, T. L.; Hobart, P. M.; Geoghegan, K. F.; Ammirati, M. J.; Danley, D. E.; O'Connor, B. A.; Hoover, D. J. X-ray Analyses of Peptide-Inhibitor Complexes Define the Structural Basis of Specificity for Human and Mouse Renins. Nature 1992, 357, 466-472.
33. (a) Lam, P. Y. S.; Eyermann, C. J.; Hodge, C. N.; Jadhav, P. K.; Ru, Y.; Bacheler, L. T.; Meek, J. L.; Otto, M. J.; Rayner, M. M.; Wong, N. Y.; Chang, C. H.; Wever, P. C.; Jackson, D. A.; Sharpe, T. R.; Erickson-Viitanen, S. De Novo Design and Discovery of Potent, Nonpeptidal HIV-1 Protease Inhibitors. 205th ACS National Meeting, Mar. 28-Apr 2, 1993; Division of Med. Chem., No. 96.
34. (b) Lam, P. Y. S.; Eyermann, C. J.; Hodge, C. N.; Jadhav, P. K.; Delucca, G. V. Substituted Cyclic Carbonyls and Derivatives Thereof Useful as Retroviral Protease Inhibitors. PCT Patent Application WO 9307128, 1993.
35. (c) Lam, P. Y. S.; Jadhav, P. K.; Eyermann, C. J.; Hodge, C. N.; Ru, Y.; Bacheler, L. T.; Meek, J. L.; Otto, M. J.; Rayner, M. M.; Wong, N. Y.; Chang, C. H.; Wever, P. C.; Jackson, D. A.; Sharpe, T. R.; Erickson-Vitanen, S. Rational Design of Potent, Bioavailable, Nonpeptide Cyclic Ureas as HIV Protease Inhibitors. Science 1994, 263, 380-384.
36. 2-Symmetric HIV-1 Protease Inhibitors from D-Mannitol. Bioorg. Med. Chem. Lett. 1992, 2, 353-356.
37. (b) Jadhav, P. K.; McGee, L. R.; Shenvi, A.; Hodge, C. N. 1,4-Diamine-2,3-dihydroxybutanes. U.S. Patent 5,294,720, Mar. 15, 1994.
38. (a) Eyermann, C. J.; et al. To be published.
39. (b) Hodge, C. N.; Straatsma, T. P.; McCammon, J. A.; Wlodawer, A. Molecular Modelling in the Discovery and Optimization of Lead Compounds. In Structural Biology of Viruses; Chiu, W., Ed.; Oxford Press: Oxford, 1996.
40. (c) Comment by Klunder, J. M. Nonpeptide Cyclic Urea Inhibitors of HIV Protease. Chemtracts-Org. Chem. 1994, 7, 82-87.
41. Dunitz, J. D. The Entropic Cost of Bound Water in Crystals and Biomolecules. Science 1994, 264, 670.
42. (a) Cram, D. J. Preorganization-From Solvents to Spherands. Angew. Chem., Int. Ed. Engl. 1986, 25, 1039-1057.
43. (b) Cram, D. J. The Design of Molecular Hosts, Guests and Their Complexes. Science 1988, 240, 760-767.
44. (a) Hamilton, H. W.; Steinbaugh, B. A.; Stewart, B. H.; Chan, O. H.; Schmid, H. L.; Schroeder, R.; Ryan, M. J.; Keiser, J.; Taylor, M. D.; Blankley, C. J.; Kaltenbronn, J. S.; Wright, J.; Hicks, J. Evaluation of Physicochemical Parameters Important to the Oral Bioavailability of Peptide-like Compounds: Implications for the Synthesis of Renin Inhibitors. J. Med. Chem. 1995, 38, 1446-1455.
45. (b) Kim, E. E.; Baker, C. T.; Dwyer, M. D.; Murcko, M. A.; Rao, B. G.; Tung, R. D.; Navia, M. A. Crystal Structure of HIV-1 Protease in complex with VX-478, a Potent and Orally bioavailable Inhibitor of the Enzyme. J. Am. Chem. Soc. 1995, 117, 1181-1182.
46. March, J. Advanced Organic Chemistry, 3rd ed.; Wiley: New York, 1985; p 125.
47. (a) Johnson, F. Allylic Strain in Six-Membered Rings. Chem. Rev. 1968, 68, 375-413.
48. (b) Hoffmann, R. W. Flexible Molecules with Defined Shape-Conformational Design. Angew. Chem., Int. Ed. Engl. 1992, 31, 1124-1134.
49. Lam, P. Y. S.; Jadhav, P. K. Unpublished data.
50. Omura, K.; Swern, D. Oxidation of Alcohols by "Activated" Dimethylsulfoxide. A Preparative, Steric and Mechanistic Study. Tetrahedron 1978, 34, 1651-1660.
51. (a) Freuidenberger, J. H.; Konradi, A. W.; Pedersen, S. F. Intermolecular Pinacol Cross Coupling of Electronically Similar Aldehydes. An Efficient and Stereoselective Synthesis of 1,2-Diols Employing a Practical Vanadium(II) Reagent. J. Am. Chem. Soc. 1989, 111, 8014-8016.
52. 2-Symmetric Diamino Alcohols and Diols for Use in HIV Protease Inhibitors. J. Org. Chem. 1992, 57, 5692-5700.
53. Roberts, S. M., Ed. Molecular Recognition: Chemical and Biochemical Problems II; Royal Society of Chemistry: Cambridge, 1992.
54. Erickson-Viitanen, S.; Klabe, R. M.; Cawood, P. G.; O'Neal, P. L.; Meek, J. L. Potency and Selectivity of Inhibition of Human Immunodeficiency Virus Protease by a Small Nonpeptide Cyclic Urea, DMP323. Antimicrob. Agents Chemother. 1994, 38, 1628-1634.
55. Bacheler, L. T.; Paul, M.; Jadhav, P. K.; Otto, M.; Stone, B.; Miller, J. An Assay for HIV RNA in Infected Cell Lysates, and Its Use for the Rapid Evaluation of Antiviral Efficacy. Antiviral Chem. Chemother. 1994, 5 (2), 111-121.
56. 18 column and methanol/water eluant.
57. Wong, N. Y.; Burcham, D. L.; Saxton, P. L.; Erickson-Viitanen, S.; Grubb, M. F.; Quon, C. Y.; Huang, S.-M. A Pharmacokinetic Evaluation of HIV Protease Inhibitors, Cyclic Ureas, in Rats and Dogs. Biopharm. Drug Dispos. 1994, 15, 535-544.
58. The complete macromolecular crystallographic method is described in detail in: Chang, C. H.; Schadt, M. C.; Lewandowski, F. A.; DeLoskey, R.; Duke, J.; Calabrese, J. C.; Lam, P. Y. S.; Jadhav, P. K.; Eyermann, C. J.; Hodge, C. N.; Weber, P. C. Three Dimensional Structures of the HIV-1 Protease Complexed with Novel Non-Peptide, Cyclic Urea-Containing Inhibitors. Manuscript in preparation.
59. (a) Grzesiek, S.; Bax, A.; Nicholson, L. K.; Yamazaki, T.; Wingfield, P.; Stahl, S. J.; Eyermann, C. J.; Torchia, D. A.; Hodge, C. N.; Lam, P. Y. S.; Jadhav, P. K.; Chang, C.-H. NMR Evidence for the Displacement of a Conserved Interior Water Molecule in HIV Protease by a Non-Peptide Cyclic Urea-Based Inhibitor. J. Am. Chem. Soc. 1994, 116, 1581-1582.
60. (b) Yamazaki, T.; Nicholson, L. K.; Torchia, D. A.; Wingfield, P.; Stahl, S. J.; Kaufman, J. D.; Eyermann, C. J.; Hodge, C. N.; Lam, P. Y. S.; Ru, Y.; Jadhav, P. K.; Chang, C.-H.; Weber, P. C. NMR and X-ray Evidence That the HIV Protease Catalytic Aspartyl Groups Are Protonated in the Complex Formed by the Protease and a Non-Peptide Cycyclic Urea-Based Inhibitor. J. Am. Chem. Soc. 1994, 16, 10791-10792.
61. (c) Nicholson, L. K.; Yamazaki, T.; Torchia, D. A.; Grzesiek, S.; Bax, A.; Stahl, S. J.; Kaufman, J. D.; Wingfield, P. T.; Lam, P. Y. S.; Jadhav, P. K.; Hodge, C. N.; Domaille, P. J.; Chang, C.-H. Flexibility and Function in HIV-1 Protease. Struct. Biol. 1995, 2 274-280.
62. (d) Yamazaki, T.; Hinck, A. P.; Wang, Y.-X.; Nicholson, L. K.; Torchia, D. A.; Wingfield, P.; Stahl, S. J.; Kaufman, J. D.; Chang, C.-H.; Domaille, P. J.; Lam, P. Y. S. Three Dimensional Solution Structure of the HIV-1 Protease Complexed with DMP323, a Novel Cyclic Urea-type Inhibitor, Determined by Nuclear Magnetic Resonce Spectroscopy. Protein Sci. 1996, 5, 495-506.
63. (a) Chenera, B.; DesJarlais, R. L.; Finkelstein, J. A.; Eggleston, D. S.; Meek, T. D.; Tomaszek, T. A.; Dryer, G. B. Nonpeptide HIV Protease Inhibitors Designed to Replace a Bound Water. Bioorg. Med. Chem. Lett. 1993, 3, 2717-2722.
64. (b) Wild, H.; Hansen, J.; Lautz, J.; Paessens, A. Preparation of 5-Oxodibenzo-(a,d)cyclohepta-1,4-diene Derivatives as Antiretroviral Agents. EP 589322-A1, 1994.
65. (c) Randad, R. S.; Pan, W.; Gulnik, S. V.; Burt, S.; Erickson, J. W. De Novo Design of Nonpeptidic HIV-1 Protease Inhibitors: Incorporation of Structural Water. Bioorg. Med. Chem. Lett. 1994, 4, 1247-1252.
66. (d) Vara Prasad, J. V. N.; et al. Novel Series of Achiral, Low Molecular Weight, and Potent HIV-1 Protese Inhibitors. J. Am. Chem. Soc. 1994, 116, 6989-6990.
67. (e) Peyman, A.; Stahl, W.; Wagner, K.; Ruppert, D.; Budt, K.-H. Non-Peptide-Based Inhibitors of Human Immunodeficiency Virus-1 Protease. Bioorg. Med. Chem. Lett. 1994, 4, 2601-2604.
68. (f) Jadhav, P. K.; Woerner, F. J. Synthesis of 8-Membered Cyclic Sulfamides: Novel HIV-1 Protease Inhibitors. Tetrahedron Lett. 1995, 36, 6383-6386.
69. (g) Sham, H. L.; Zhao, C.; Stewart, K. D.; Betebenner, D. A.; Lin, S.; Park, C. H.; Kong, X.-P.; Rosenbrook, W., Jr.; Herrin, T.; Madigan, D.; Vasavanonda, S.; Lyons, N.; Molla, A.; Saldivar, A.; Marsh, K. C.; McDonald, E.; Wideburg, N. E.; Denissen, J. F.; Robins, T.; Kempf, D. J.; Plattner, J. J.; Norbeck, D. W. A Novel, Picomolar Inhibitor of Human Immunodeficiency Virus Type 1 Protease. J. Med. Chem. 1996, 39, 392-397.
70. (h) Nugiel, D. A.; Jacobs, K.; Worley, T.; Patel, M.; Kaltenbach, R. F., III; Meyer, D. T.; Jadhav, P. K.; De Lucca, G. V.; Smyser, T. E.; Klabe, R. M.; Bacheler, L. T.; Rayner, M. M.; Seitz, S. P. Preparation and SAR of Novel P1/P1′ Substituted Cyclic Urea Based HIV-1 Protease Inhibitors. J. Med. Chem. 1996, 39, 2156-2169.
71. (a) Lunney, E. A.; Hagen, S. E.; Domagala, J. M.; Humblet, C.; Kosinski, J.; Tait, B. D.; Warmus, J. S.; Wilson, M.; Ferguson, D.; Hupe, D.; Tummino, P. T.; Baldwin, E. T.; Bhat, T. N.; Liu, B.; Erickson, J. W. A Novel Nonpeptide HIV-1 Protease Inhibitor: Elucidation of the Binding Mode and Its Application in the Design of Related Analogs. J. Med. Chem. 1994, 37, 2664-2677.
72. (b) Prasad, J. V. N. V.; Para, K. S.; Lunney, E. A.; Ortwine, D. F.; Dunbar, J. B.; Ferguson, D.; Tummino, P. J.; Hupe, D.; Tait, B. D.; Domagala, J. M.; Humblet, C.; Bhat, T. N.; Liu, B.; Guerin, D. M. A.; Baldwin, E. T.; Erickson, J. W.; Sawyer, T. K. Novel Series of Achiral, Low Molecular Weight, and Potent HIV-1 Protease Inhibitors. J. Am. Chem. Soc. 1994, 116, 6989-6990.
73. (c) Prasad, J. V. N. V.; Para, K. S.; Tummino, P. J.; Ferguson, D.; McQuade, T. J.; Lunney, E. A.; Rapundalo, S. T.; Batley, B. L.; Hingorani, G.; Domagala, J. M.; Gracheck, S. J.; Bhat, T. N.; Liu, B.; Baldwin, E. T.; Erickson, J. W.; Sawyer, T. K. Nonpeptidic Potent HIV-1 Protease Inhibitors: (4-Hydroxy-6-phenyl-2-oxo-2H-pyran-3-yl)thiomethanes That Span P1-P2′ Subsites in a Unique Mode of Active Site Binding. J. Med. Chem. 1995, 38, 898-905.
74. (d) Thaisrivongs, S.; Tomich, P. K.; Watenpaugh, K. D.; Chong, K.-T.; Howe, W. J.; Yang, C.-P.; Strohbach, J. W.; Turner, S. R.; McGrath, J. P.; Bohanon, M. J.; Lynn, J. C.; Mulichak, A. M.; Spinelli, P. A.; Hinshaw, R. R.; Pagano, P. J.; Moon, J. B.; Ruwart, M. J.; Wilkinson, K. F.; Rush, B. D.; Zipp, G. L.; Dalga, R. J.; Schwende, F. J.; Howard, G. M.; Padbury, G. E.; Toth, L. N.; Zhao, Z.; Koeplinger, K. A.; Kakuk, T. J.; Cole, S. L.; Zaya, R. M.; Piper, R. C.; Jeffrey, P. Structure-Based Design of HIV Protease Inhibitors: 4-Hydroxycoumarins and 4-Hydroxy-2-pyrones as Nonpeptidic Inhibitors. J. Med. Chem. 1994, 37, 3200-3204.
75. (e) Romines, K. R.; Watenpaugh, K. D.; Tomich, P. K.; Howe, W. J.; Morris, J. K.; Lovasz, K. D.; Mulichak, A. M.; Finzel, B. C.; Lynn, J. C.; Horng, M.-M.; Schwende, F. J.; Ruwart, M. J.; Zipp, G. L.; Chong, K.-T.; Dolak, L. A.; Toth, L. N.; Howard, G. M.; Rush, B. D.; Wilkinson, K. F.; Possert, P. L.; Dalga, R. J.; Hinshaw, R. R. Use of Medium-Sized Cycloalkyl Rings to Enhance Secondary Binding: Discovery of a New Class of Human Immunodeficiency Virus (HIV) Proteases Inhibitors. J. Med. Chem. 1995, 38, 1884-1891.
76. (f) Thaisrivongs, S.; Watenpaugh, K. D.; Howe, W. J.; Tomich, P. K.; Dolak, L. A.; Chong, K.-T.; Tomich, C.-S.; Tomasselli, A. G.; Turner, S. R.; Strohbach, J. W.; Mulichak, A. M.; Janakiraman, M. N.; Moon, J. B.; Lynn, J. C.; Horng, M.-M.; Hinshaw, R. R.; Curry, K. A.; Rothrock, D. J. Structure-Based Design of Novel Protease Inhibitors: Carboxamide-Containing 4-Hydroxycoumarins and 4-Hydroxy-2-pyrones as Potent Nonpeptidic Inhibitors. J. Med. Chem. 1995, 38, 3624-3637.
77. (g) Romines, K. R.; Watenpaugh, K. D.; Howe, W. J.; Tomich, P. K.; Lovasz, K. D.; Morris, J. K.; Janakiraman, M. N.; Lynn, J. C.; Horng, M.-M.; Chong, K.-T.; Hinshaw, R. R.; Dolak, L. A. Structure-Based Design of Nonpeptidic HIV Protease Inhibitors from a Cyclooctylpyranone Lead Structure. J. Med. Chem. 1995, 38, 4463-4473.
78. Hodge, C. N.; Ru, Y.; Aldrich, P. E.; Lam, P. Y. S.; Jadhav, P. K.; DeLucca, G. V.; Kaltenbach, R. F., III; Chang, C. H.; Fernandez, C. H.; Holler, E. E.; Woerner, F. J.; Calabrese, J. C.; Daneker, W. K.; Emmett, G. C. Calculated and Experimental Conformations of Cyclic Urea Inhibitors of HIV Protease. Manuscript in preparation.
79. Small-molecule crystal structures solved by J. C. Calabrese of E. I. DuPont de Nemours & Co. Inc. See Supporting Information for complete methods and coordinates.
80. Rich, D. H. Effect of Hydrophobic Collapse on Enzyme-Inhibitor Interaction. Implication for the Design of Peptidal Mimetics. In Perspectives in Medicinal Chemistry; Testa, B.; Kyburz, E., Fuhrer, W., Giger, R., Eds.; VCH: New York, 1993; pp 15-25.
81. (a) Otto, M. J.; Reid, C. D.; Garber, S.; Lam, P. Y. S.; Scarnati, H.; Bacheler, L. T.; Rayner, M. M.; Winslow, D. L. Rational Design of Potent, Bioavailable, Nonpeptide Cyclic Ureas as HIV Protease Inhibitors. Antimicrob. Agents Chemother. 1993, 37, 2606-2611.
82. (b) Rayner, M. M.; Cordova, B. C.; Meade, R. P.; Aldrich, P. E.; Jadhav, P. K.; Ru, Y.; Lam, P. Y. S. DMP323, a Nonpeptide Cyclic Urea Inhibitor of Human Immunodeficiency Virus (HIV) Protease, Specifically and Persistently Blocks Intracellular Processing of HIV gag Polyprotein. Antimicrob. Agents Chemother. 1994, 38, 1635-1640.
83. (c) Grubb, M. F.; Wong, Y. N.; Burcham, D. L.; Saxton, P. L.; Quon, C. Y.; Huang, S.-M. Pharmacokinetics of HIV Protease Inhibitor DMP323 in Rats and Dogs. Drug Metab. Dispos. 1994, 22, 709-712.
84. Shum, L. I.; Winslow, D. L.; Kornhauser, D. M.; et al. Unpublished data. The metabolic instability of the benzyl alcohol of DMP323 was also of concern.
85. Hodge, C. N.; Aldrich, P. E.; Bacheler, L. T.; Chang, C.-H.; Eyermann, C. J.; Grubb, M. F.; Jackson, D. A.; Jadhav, P. K.; Korant, B.; Lam, P. Y. S.; Maurin, M. B.; Meek, J. L.; Otto, M. J.; Rayner, M. M.; Sharpe, T. R.; Shum, L.; Winslow, D. L.; Erickson-Viitanen, S. DMP450: An Orally Bioavailable Cyclic Urea Inhibitor of the HIV Protease. Chem. Biol. 1996, 3, 301-314. Avid Pharmaceutical Co. (Philadelphia, PA) has recently acquired the option to license DMP450.